AB Science (A8D) Stock Overview
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
A8D Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AB Science S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.16 |
| 52 Week High | €2.06 |
| 52 Week Low | €0.73 |
| Beta | 1.66 |
| 1 Month Change | -13.73% |
| 3 Month Change | -15.12% |
| 1 Year Change | 19.30% |
| 3 Year Change | -85.91% |
| 5 Year Change | -87.90% |
| Change since IPO | -90.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| A8D | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -1.6% | -1.6% |
| 1Y | 19.3% | -16.4% | 13.0% |
Return vs Industry: A8D exceeded the German Pharmaceuticals industry which returned -16.4% over the past year.
Return vs Market: A8D exceeded the German Market which returned 13% over the past year.
Price Volatility
| A8D volatility | |
|---|---|
| A8D Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A8D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: A8D's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 36 | Alain Moussy | www.ab-science.com |
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors.
AB Science S.A. Fundamentals Summary
| A8D fundamental statistics | |
|---|---|
| Market cap | €89.29m |
| Earnings (TTM) | -€8.54m |
| Revenue (TTM) | €1.03m |
Is A8D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A8D income statement (TTM) | |
|---|---|
| Revenue | €1.03m |
| Cost of Revenue | €95.00k |
| Gross Profit | €932.00k |
| Other Expenses | €9.47m |
| Earnings | -€8.54m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 90.75% |
| Net Profit Margin | -831.45% |
| Debt/Equity Ratio | -66.6% |
How did A8D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 14:53 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AB Science S.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Keay Nakae | Chardan Capital Markets, LLC |
| Jean-Pierre Loza | In Extenso Financement & Marché |